Compare AbbVie Inc (ABBV) vs Infosys Limited (INFY) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

INFY trades at $10.88, down 2.51% on the day, with a bearish technical signal from moving averages. The company reported strong profitability with a net income margin of 16.44% and ROE of 31.57% for 2025, while recent earnings have mostly beaten expectations. Analyst consensus is a 'Hold' with a $13.18 price target, suggesting potential upside. Recent news highlights multiple AI collaborations, such as with Sentara and GlobalFoundries, indicating strategic focus on AI-driven growth.

The outlook for INFY is mixed; fundamentals remain solid with steady revenue growth and high profitability, but technical indicators and sector-wide demand concerns pose near-term risks. The stock presents a value opportunity given its low P/E of 13.6, though investors face volatility from competitive pressures and macroeconomic headwinds affecting IT spending.